论文信息 - First-in-class DAPK1/CSF1R dual inhibitors: Discovery of 3,5-dimethoxy-N-(4-(4-methoxyphenoxy)-2-((6-morpholinopyridin-3-yl)amino)pyrimidin-5-yl)benzamide as a potential anti-tauopathies agent. - 字舞流文

First-in-class DAPK1/CSF1R dual inhibitors: Discovery of 3,5-dimethoxy-N-(4-(4-methoxyphenoxy)-2-((6-morpholinopyridin-3-yl)amino)pyrimidin-5-yl)benzamide as a potential anti-tauopathies agent.

Ki Duk Park | M. Oh | E. Roh | Ahmed H. Hassan | J. Choi | Yun-Kyung Kim | A. K. Farag | Youngji Kwon | Hyeanjeong Jeong | Ahmed H. E. Hassan